Corporate Profile

Corporate Profile

Aileron Therapeutics is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using our proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Our focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept we call “chemoprotection.” ALRN-6924 is currently being evaluated in a Phase 1b/2 clinical trial to assess ALRN-6924 as a chemoprotection agent in small-cell lung cancer patients being treated with the chemotherapy topotecan. Our long-term vision is to protect cancer patients across a variety of chemotherapies for many different cancer indications.